GlassScriptPhysician profile
Verne H Webster
NPI 1932163920
$7,771.34
in general payments reported to CMS, 2019-2025
43 companies · $771 in 2025
The $771 reported for 2025 was more than what 81% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $726 · 2020: $1,231 · 2021: $1,362 · 2022: $1,088 · 2023: $1,300 · 2024: $1,294 · 2025: $771.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,364.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,364.30 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,163.09 | 2019-2025 | Vraylar, Qulipta, Ubrelvy |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,042.73 | 2019-2025 | Relistor, Xifaxan, Trulance |
| Novo Nordisk INC | $769.02 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $428.18 | 2019-2025 | Farxiga, Breztri |
| Antares Pharma, INC. | $390.16 | 2019-2025 | Xyosted, Tlando, Nocdurna |
| Indivior INC. | $376.68 | 2019-2025 | Sublocade |
| Lilly USA, LLC | $350.86 | 2019-2024 | Mounjaro, Zepbound |
| Alkermes, INC. | $307.43 | 2021-2025 | Vivitrol, Vivitrol |
| Collegium Pharmaceutical, INC. | $283.39 | 2019-2023 | Xtampza |
| Bayer Healthcare Pharmaceuticals INC. | $227.60 | 2022-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $227.14 | 2024-2025 | Caplyta |
| Allergan, INC. | $203.09 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $181.70 | 2019-2023 | Verquvo, Belsomra |
| Abbott Laboratories | $179.16 | 2021-2024 | Freestyle Libre 3 |
| Glaxosmithkline, LLC. | $175.37 | 2020-2024 | Trelegy Ellipta, Shingrix |
Show all 43 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Verne Webster listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.